Breast cancer questions focus on receptor status and treatment, hereditary risk and screening intervals.
Types
Invasive ductal carcinoma is most common. Invasive lobular carcinoma shows loss of E-cadherin and a targetoid pattern. Paget disease of the nipple shows eczema and underlying carcinoma. Inflammatory breast cancer involves dermal lymphatics (peau d'orange).
Treatment by receptor
ER or PR positive tumors respond to tamoxifen (endometrial hyperplasia risk) or aromatase inhibitors (osteoporosis risk). HER2 positive tumors respond to trastuzumab (cardiotoxicity). Triple negative tumors need chemotherapy.
Genetics and screening
BRCA1 and BRCA2 raise breast and ovarian cancer risk; BRCA2 raises male breast and prostate cancer risk. Average-risk screening mammography is offered starting between 40 and 50, every one to two years, depending on the guideline. A palpable mass in a young woman is evaluated with ultrasound.
Keep going in hematology and oncology
- Chemotherapy drugs: mechanisms and toxicities
- Paraneoplastic syndromes and oncologic emergencies
- Porphyrias, lead poisoning and heme synthesis
- Microcytic anemia: iron deficiency, thalassemia and anemia of chronic disease